GSK fires pair of COVID and RSV lawsuits at Moderna

UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.

Americas

Moderna wins reprieve in COVID-19 vaccine dispute

3 October 2024 Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Europe

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.